Medrx Co

Medrx Co Net Change in Cash

The Net Change in Cash of Medrx Co (4586.T) as of Nov 19, 2026 is -222.97 M JPY. In the previous year, Net Change in Cash was 256.92 M JPY — a change of -186.79% (lower).

Net Change in Cash

-222.97 MJPY

YoY

-186.79%

Last updated:

Net Change in Cash of Medrx Co is 2025 -222.97 M JPY. Net Change in Cash of Medrx Co was 2024 256.92 M JPY. It decreases by -186.79% lower compared to the previous year.

The Medrx Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
670.08 M JPY
Jan 1, 2019
-386.08 M JPY
Jan 1, 2020
401.57 M JPY
Jan 1, 2021
-108.72 M JPY
Jan 1, 2022
-709.62 M JPY
Jan 1, 2023
726.70 M JPY
Jan 1, 2024
256.92 M JPY
Jan 1, 2025
-222.97 M JPY
The Medrx Co Net Change in Cash history
YEARNet Change in CashYoY
-222.97 MJPY-186.79%
256.92 MJPY-64.65%
726.70 MJPY-202.41%
-709.62 MJPY+552.73%
-108.72 MJPY-127.07%
401.57 MJPY-204.01%
-386.08 MJPY-157.62%
670.08 MJPY-144.28%
-1.51 BJPY-362.21%
577.08 MJPY-180.43%
-717.46 MJPY-37.98%
-1.16 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Net Change in Cash of Medrx Co is -222.97 M JPY in 2025.

Net Change in Cash of Medrx Co changed from 256.92 M JPY to -222.97 M JPY, representing a -186.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medrx Co

All Key Metrics — Medrx Co